Abstract
Objective
The study aimed to present long-term outcomes of near-total removal of facial nerve schwannomas (FNS) with good facial nerve function (HB Grade III or better).
Methods
We successfully performed near-total removal of FNS (tumor removal of 95% or greater) on 13 cases, and the remaining 6 cases who failed underwent total tumor removal and nerve grafting. Patients were divided into near-total removal group and total removal group according to surgical approach, and they were followed up for 7.38 ± 1.98 years (range, 5 to 11 years) and 6.66 ± 1.63 years (range, 5 to 9 years), respectively.
Results
12 of 13 cases (92.3%) in the near-total removal group successfully maintained at least Grade III except one who recurred and underwent complete tumor removal and nerve grafting, and 10 cases (76.9%) achieved Grade I or Grade II. 5 of 6 cases (83.3%) in the total removal group obtained Grade III, but none recovered to Grade I or II. Tumor growth was noted in only one case (7.7%) among the near-total removal group during the follow-up.
Conclusions
Long-term outcomes of near-total removal of FNS were favorable, which may be a good choice for the old patients with good facial nerve function.
1
Introduction
Facial nerve schwannomas (FNS) are rare entities. There is no clear consensus about treatment. Currently, most authors agree that the ultimate goal is to preserve facial nerve function due to the slow-growing and benign nature of the tumors. Total tumor removal and nerve grafting undoubtedly result in Grade III (House–Brackmann grading system ) recovery at best , thus subtotal removal, observation, stereotactic radiosurgery or facial nerve decompression sole is recommended to the patients with good facial nerve function (Grade III or better), since good outcomes of facial nerve could be maintained for a time .
The purpose of the current study was to report long-term outcomes of near-total removal of FNS and discuss about its application.
2
Materials and methods
A consecutive series of 19 FNS patients with good facial nerve function was involved in the study, among which 11 were female and 8 male. The mean age was 36.20 ± 3.22 years (range, 18 to 72 years). We successfully carried out near-total removal of FNS (defined as tumor removal of 95 percentage or greater) on 13 cases under high magnification and intraoperative facial nerve monitoring, and the other 6 cases who were found to have unclear border between nerve shaft and the tumors underwent total tumor removal and nerve grafting. They were divided into the near-total removal group and the total removal group, and followed up for 7.38 ± 1.98 years (range, 5 to 11 years) and 6.66 ± 1.63 years (range, 5 to 9 years), respectively. MRI examination was performed on each patient before surgery, three months after surgery and each year thereafter. Hearing level was measured by audiometer.
During the surgery, intraoperative facial nerve monitoring was used to identify facial nerve from the tumors. A cut was made through the tumors near its junction with facial nerve. The tumor capsule was left, and other tumor tissues were all removed. Nerve sheath was preserved.
The selection of surgical approach was mainly dependent on tumor location. Middle cranial fossa approach was selected when the tumors affected internal auditory canal segment, cerebellar pontine angle segment, labyrinthine segment or geniculate ganglion of facial nerve, and transmastoid approach was considered when tympanic segment or mastoid segment was affected. Middle cranial fossa combined with transmastoid approach was adopted when both the former and latter sites were involved. There were no noticeable complications.
2
Materials and methods
A consecutive series of 19 FNS patients with good facial nerve function was involved in the study, among which 11 were female and 8 male. The mean age was 36.20 ± 3.22 years (range, 18 to 72 years). We successfully carried out near-total removal of FNS (defined as tumor removal of 95 percentage or greater) on 13 cases under high magnification and intraoperative facial nerve monitoring, and the other 6 cases who were found to have unclear border between nerve shaft and the tumors underwent total tumor removal and nerve grafting. They were divided into the near-total removal group and the total removal group, and followed up for 7.38 ± 1.98 years (range, 5 to 11 years) and 6.66 ± 1.63 years (range, 5 to 9 years), respectively. MRI examination was performed on each patient before surgery, three months after surgery and each year thereafter. Hearing level was measured by audiometer.
During the surgery, intraoperative facial nerve monitoring was used to identify facial nerve from the tumors. A cut was made through the tumors near its junction with facial nerve. The tumor capsule was left, and other tumor tissues were all removed. Nerve sheath was preserved.
The selection of surgical approach was mainly dependent on tumor location. Middle cranial fossa approach was selected when the tumors affected internal auditory canal segment, cerebellar pontine angle segment, labyrinthine segment or geniculate ganglion of facial nerve, and transmastoid approach was considered when tympanic segment or mastoid segment was affected. Middle cranial fossa combined with transmastoid approach was adopted when both the former and latter sites were involved. There were no noticeable complications.
3
Results
Summary of the patients in near-total removal group and total removal group is in Tables 1 and 2 . Facial paralysis was firstly presented in 14 of 19 cases (73.7%), followed by hearing loss in 9 of 19 cases (45.0%) and vertigo in 2 of 19 cases (10.5%). Geniculate ganglion and/or labyrinthine segment were most commonly affected (12 cases, 63.2%), followed by tympanic segment (8 cases, 42.1%), mastoid segment (7 cases, 36.8%), internal auditory canal segment (7 cases, 36.8%), and CPA segment (one case, 5.3%). Multi-segment involvement (12 cases, 63.2%) was more common than single-segment involvement.
No. | Symptoms | Segments affected | PreFNF | PosFNF | Surgical approach | Initial hearing level | Final hearing level | Recurrence | Follow-up (years) |
---|---|---|---|---|---|---|---|---|---|
1 | SNHL, T | IAC | II | II | MCF | 30 dB | 30 dB | No | 6 |
2 | FP | IAC | II | II | MCF | Normal | Normal | No | 8 |
3 | FP, V | GG, LS | II | II | MCF | Normal | Normal | No | 6 |
4 | FP, CHL | GG, TS, MS | III | IV | TM, MCF | 40 dB | 25 dB | No | 5 |
5 | T, MHL | LS, TS, MS | I | I | TM, MCF | 35 dB | 30 dB | No | 7 |
6 | T | IAC, GG | I | I | MCF | Normal | Normal | Yes | 9 |
7 | FP | CPA | III | II | MCF | Normal | Normal | No | 7 |
8 | CHL, T | TS, MS | I | I | TM | 30 dB | 20 dB | No | 5 |
9 | FP | GG, TS | II | II | TM, MCF | Normal | Normal | No | 8 |
10 | CHL, T | LS, TS, MS | I | I | TM, MCF | 40 dB | 25 dB | No | 9 |
11 | FP, CHL | GG, TS, MS | III | II | TM, MCF | 55 dB | 30 dB | No | 10 |
12 | FP | IAC | III | III | MCF | Normal | Normal | No | 11 |
13 | PF | GG | II | I | MCF | Normal | Normal | No | 5 |